Leerink Partnrs Issues Optimistic Forecast for NRIX Earnings

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - Equities researchers at Leerink Partnrs lifted their Q3 2025 earnings per share estimates for shares of Nurix Therapeutics in a report released on Wednesday, July 9th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings of ($0.96) per share for the quarter, up from their previous forecast of ($0.99). The consensus estimate for Nurix Therapeutics' current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for Nurix Therapeutics' Q4 2025 earnings at ($0.99) EPS, FY2025 earnings at ($3.14) EPS, Q1 2026 earnings at ($1.03) EPS, Q2 2026 earnings at ($1.09) EPS, Q3 2026 earnings at ($1.15) EPS, Q4 2026 earnings at ($1.01) EPS and FY2026 earnings at ($4.27) EPS.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.27. The firm had revenue of $44,056 billion during the quarter, compared to analyst estimates of $16.26 million. Nurix Therapeutics had a negative return on equity of 45.26% and a negative net margin of 234.57%.

Several other equities analysts have also issued reports on the company. Wall Street Zen raised Nurix Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, June 21st. Wells Fargo & Company decreased their target price on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday, April 9th. Morgan Stanley set a $16.00 target price on Nurix Therapeutics and gave the stock an "equal weight" rating in a research report on Tuesday. Stifel Nicolaus decreased their target price on Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. Finally, Stephens reissued an "overweight" rating and issued a $30.00 target price on shares of Nurix Therapeutics in a research report on Thursday, July 10th. Four research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $29.31.

Nurix Therapeutics Stock Performance

Shares of NRIX traded down $0.33 during trading hours on Monday, hitting $12.09. The company had a trading volume of 767,450 shares, compared to its average volume of 848,478. The firm has a fifty day moving average price of $11.43 and a 200-day moving average price of $13.65. The stock has a market capitalization of $924.28 million, a price-to-earnings ratio of -4.63 and a beta of 2.15. Nurix Therapeutics has a 52-week low of $8.18 and a 52-week high of $29.56.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC boosted its position in shares of Nurix Therapeutics by 1,711.9% during the 4th quarter. FMR LLC now owns 10,634,231 shares of the company's stock valued at $200,349,000 after acquiring an additional 10,047,329 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Nurix Therapeutics by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 4,415,122 shares of the company's stock valued at $52,452,000 after acquiring an additional 69,856 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Nurix Therapeutics by 3.0% during the 4th quarter. Wellington Management Group LLP now owns 3,586,605 shares of the company's stock valued at $67,572,000 after acquiring an additional 104,500 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of Nurix Therapeutics by 2.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 2,428,283 shares of the company's stock valued at $28,849,000 after acquiring an additional 47,855 shares during the last quarter. Finally, Soleus Capital Management L.P. boosted its position in shares of Nurix Therapeutics by 97.3% during the 4th quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company's stock valued at $39,617,000 after acquiring an additional 1,036,999 shares during the last quarter.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,377 shares of the company's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the transaction, the insider directly owned 61,516 shares in the company, valued at $707,434. This represents a 5.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Houte Hans Van sold 6,198 shares of the company's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.33, for a total value of $70,223.34. Following the completion of the transaction, the chief financial officer owned 33,724 shares of the company's stock, valued at $382,092.92. The trade was a 15.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,013 shares of company stock valued at $137,096 over the last 90 days. 7.40% of the stock is currently owned by corporate insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.